Gut Microbiota in People With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma Clinical Trial

Official title: Gut Microbiota in Patients With HCC

Status Withdrawn

Clinical Trial Summary

Background:

There are about 100 trillion microbial cells in a person s gut. This is called the human gut microbiota. When this is disrupted, it can lead to many diseases. Studies show that the gut microbiota in people with cancer is different than that found in healthy people. Researchers want to study links between the gut microbiota and the immune system in people with a liver disease called hepatocellular carcinoma (HCC).

Objective:

To study links between gut microbiota and the immune system in people with HCC.

Eligibility:

People at least 18 years old with HCC. They must be scheduled to have tumors removed by surgery.

Design:

• People having surgery for primary liver tumors at the Mount Sinai Medical Center will be screened for this study.

• At the initial visit, blood, rectal swabs, urine, and stool will be collected. Participants will answer questions about their medical condition.

• Before surgery, blood, rectal swabs, urine, and stool will be collected. This will be done at a routine visit.

• When they have surgery, a piece of liver tissue with the tumor will be collected. This will be sent to the National Cancer Institute for tests.

• After surgery, blood, rectal swabs, urine, and stool will be collected 3 times. This will be done at routine visits.

Clinical Trial Description

Background:

The human gut microbiota consists of approximately 100 trillion microbial cells whose disruption leads to many diseases including inflammatory bowel disease and colorectal cancer to name a few. Recent studies have shown that cancer patients have an altered gut microbiota when compared to healthy controls. Intestinal microbiota has been proposed to contribute to the start and progression of a number of liver diseases, such as alcoholic liver disease (ALD), nonalcoholic steatohepatitis (NASH), liver cirrhosis, hepatic encephalopathy (HE), and hepatocellular carcinoma (HCC). We plan to investigate the relationship between the gut microbiota and the immune system in patients with HCC. In recent years, immune regulation at the level of the tumor microenvironment has become very important in different types of cancer.

Objectives:

To collect blood/stool/urine/tumor samples and rectal swabs from HCC patients undergoing resection of primary liver tumors at the Mount Sinai Medical Center and to perform an analysis of the interaction of tumors, immune responses and the gut microbiome.

Eligibility:

• Patients 18 years of age and older

• Patients undergoing liver resection for primary liver cancer

• Patients must be willing to provide informed consent

Design

• Blood, stool, rectal swabs, urine and/or tumor samples may be collected from consenting subjects seen at Mount Sinai Medical Center at the initial visit and/or at follow-up visits.

• Tumor samples will only be obtained from patients undergoing surgery.

• Patients will be asked to answer a questionnaire. ;

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma
• Liver Cancer
• Liver Cell Caricinoma
• Liver Neoplasm
• Liver Neoplasms

• NCT number: NCT02599909
• Study type: Observational
• Source: National Institutes of Health Clinical Center (CC)
• Status: Withdrawn
• Start date: November 6, 2015
• Completion date: September 14, 2018